

# Jazz Pharmaceuticals to Participate in the Jefferies Healthcare Conference

## June 1, 2022

DUBLIN, June 1, 2022 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the Company will participate in the Jefferies Healthcare Conference on Wednesday, June 8, 2022, at 11:00 a.m. PT / 2:00 p.m. ET / 7:00 p.m. IST in New York.

An audio webcast of the presentation will be available via the Investors section of the Jazz Pharmaceuticals website at <u>www.jazzpharmaceuticals.com</u>. A replay of the webcast will be archived on the website for 30 days.

### About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc (NASDAQ: JAZZ) is a global biopharmaceutical company whose purpose is to innovate to transform the lives of patients and their families. We are dedicated to developing life-changing medicines for people with serious diseases – often with limited or no therapeutic options. We have a diverse portfolio of marketed medicines and novel product candidates, from early- to late-stage development, in neuroscience and oncology. Within these therapeutic areas, we are identifying new options for patients by actively exploring small molecules and biologics, and through innovative delivery technologies and cannabinoid science. Jazz is headquartered in Dublin, Ireland and has employees around the globe, serving patients in nearly 75 countries. For more information, please visit <u>www.jazzpharmaceuticals.com</u> and follow @JazzPharma on Twitter.

### Contacts:

Investors: Andrea N. Flynn, Ph.D. Vice President, Head, Investor Relations Jazz Pharmaceuticals plc InvestorInfo@jazzpharma.com Ireland +353 1 634 3211 U.S. +1 650 496 2717

## Media:

Kristin Bhavnani Head of Global Corporate Communications Jazz Pharmaceuticals plc <u>CorporateAffairsMediaInfo@jazzpharma.com</u> Ireland +353 1 637 2141 U.S. +1 215 867 4948



C View original content to download multimedia: <u>https://www.prnewswire.com/news-releases/jazz-pharmaceuticals-to-participate-in-the-jefferies-healthcare-conference-301559434.html</u>

SOURCE Jazz Pharmaceuticals plc